IMPLANTABLE CELLULAR AND BIOTHERAPEUTIC AGENT DELIVERY CANISTER

• US 20170319472A1
• Filed: 06/06/2015
• Published: 11/09/2017
• Est. Priority Date: 06/06/2014
• Status: Active Grant

• Current Assignee: NanoVault Medical LLC
• Original Assignee: NanoVault Medical LLC
• Inventors: Hennemann, Willard W., Steelman, Bryan L., Webster, Thomas J.
• Granted Patent: US 10,092,507 B2
• Time in Patent Office: Days
• CPC Class Codes: A61F 2/022 Artificial gland structures using bioreactors hemodialysis A61M1/16; hemofiltration A61M1/34; other extracorporeal blood treatment A61M1/36
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/397 having four-membered rings, e.g. azetidine
• CPC Class Codes: A61K 31/436 the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• CPC Class Codes: A61K 31/65 Tetracyclines
• CPC Class Codes: A61K 31/7036 having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 38/14 Peptides containing saccharide radicals; Derivatives thereof , e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
• CPC Class Codes: A61K 38/1866 Vascular endothelial growth factor [VEGF]
• CPC Class Codes: A61K 38/22 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35
• CPC Class Codes: A61K 39/395 Antibodies agglutinins A61K38/36 ; as drug carriers A61K47/50; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• CPC Class Codes: A61K 47/02 Inorganic compounds
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61M 2039/0261 Means for anchoring port to the body, or ports having a special shape or being made of a specific material to allow easy implantation/integration in the body
• CPC Class Codes: A61M 2039/027 having a particular valve, seal or septum septum A61M2039/0036
• CPC Class Codes: A61M 2039/0276 for introducing or removing fluids into or out of the body
• CPC Class Codes: A61M 2205/04 implanted
• CPC Class Codes: A61M 39/0247 Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body peritoneal dialysis catheters A61M1/285; tracheostomy devices A61M16/0465; measuring pressure within the body A61B5/03; colostomy devices A61F5/445; gastrotomy feeding tubes A61J15/0015; means for fixing a feeding tube outside of the body A61J15/0053

Abstract

The invention relates to a metallic, nanoporous canister used to encapsulate cellular and/or biotherapeutic agents. The device is biocompatible and functions to wholly isolate a therapeutically active agent and/or cells therein. Their implantation, and survival in vivo, permits the local or systemic diffusion of their encapsulated cellular and/or biomolecular and therapeutics factors with the potential to promote repair of damaged or degenerated tissues in mammalian hosts, primarily humans.

Claims

1. (1) An implantable canister for containing and delivering metabolically active agents, comprising:

(a) a metallic shell configured to possess nanoscale through-porous membrane characteristics, the shell defining a first major surface and a second major surface;

(b) an interior chamber between the first major surface and second major surface; and

(c) means allowing fluid communication with the interior chamber.

2. (2) The canister of claim 1 further comprising the nanoscale through-porous membrane morphology having a range between approximately 20 nm to 5000 nm, wherein nutrients, oxygen and metabolites are efficiently exchanged and supports canister vascularization when implanted.

3. (3) The canister of claim 1 wherein the metallic material is selected from the group consisting of cobalt-chromium based alloys, platinum based alloys, titanium based alloys, nickel-titanium based, nickel-cobalt based alloys, and stainless steel based alloys.

4. (4) The canister of claim 1 wherein the fluid communication means comprises a port.

5. (5) The canister of claim 4 wherein the port is covered by a re-sealable membrane.

6. (6) The canister of claim 5 further comprising an extended tube is attached to the port.

7. (7) The canister of claim 1 further comprising the interior chamber is configured to have internal raised channels.

8. (8) The canister of claim 7 wherein the internal raised channels are continuous.

9. (9) The canister of claim7 further comprising a plurality of internal baffles wherein the internal raised channels are separate from each other.

10. (10) The canister of claim 1 wherein the interior chamber is divided into a plurality of separate and independent internal chambers.

11. (11) The canister of claim 1 wherein the nanoscale through-porous membrane further comprises a biocontinuous morphology.

13. (13) The canister of claim 1 further comprising the nanoscale through-porous membrane morphology has a range between approximately 20 nm to 5000 nm, wherein nutrients, oxygen and metabolites are efficiently exchanged and supports canister vascularization when implanted.

12. (12) An implantable canister for containing and delivering metabolically active agents, comprising:

(a) a metallic shell configured to possess nanoscale through-porous membrane characteristics, the shell defining a first major surface and a second major surface and a side surface separating the first major surface and the second major surface;

(b) an interior chamber between the first major surface and second major surface; and

(c) means allowing fluid communication with the interior chamber.

14. (14) The canister of claim 12 wherein the metallic material is selected from the group consisting of cobalt-chromium based alloys, platinum alloys based, titanium alloys based, nickel-titanium based alloys, and stainless steel based alloys.

15. (15) The canister of claim 12 wherein the fluid communication means comprises a port.

16. (16) The canister of claim 15 wherein the port is covered by a re-sealable membrane.

17. (17) The canister of claim 16 further comprising an extended tube is attached to the port.

18. (18) The canister of claim 12 further comprising the interior chamber is configured to have internal channels.

19. (19) The canister of claim 18 wherein the internal channels are continuous.

20. (20) The canister of claim 18 further comprising a plurality of internal baffles wherein the internal channels are separate from each other.